MR-proADM, copeptin and MR-proANP significantly correlate with the main adverse outcomes in severe COVID-19 patients admitted to the ICU during the first waves, likely deserving to be evaluated in the future together with the SOFA, SAPS II and MuLBSTA prognostic scores. This evidence concerns the gene AVP and COVID-19.